X4 Pharma Q2 net loss $55.7M; WHIM NDA on track; chronic neutropenia data promising

X4 Pharmaceuticals, Inc

2023-Q3 EPS reported -$0.51

Net loss of $55.7M in Q2 2023 includes $29.9M non-cash warrant adjustment; cash $142.3M at June 30.
NDA submission for mavorixafor in WHIM syndrome on track for early 2H 2023; potential US approval in 1H 2024.
Preliminary Phase 2 chronic neutropenia data: mavorixafor increased ANC and enabled G-CSF dose reductions in 3 patients.
Raised ~$65M via PIPE in May 2023; post-quarter expanded debt facility to $115M with $22.5M initial drawdown.
Appointed Dr. Christophe Arbet-Engels as Chief Medical Officer; new mavorixafor composition-of-matter patent through 2038.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

X4 Pharmaceuticals, Inc reported financial results for the second quarter ended June 30, 2023.

Period: the second quarter ended June 30, 2023
Result: reported results

Exact text from the filing

On August 10, 2023, X4 Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its financial results and other business highlights for the second quarter ended June 30, 2023.

View on SEC.gov

59 earnings releases filed in the last 30 days. Browse all earnings releases →

X4 Pharmaceuticals, Inc filing history →

Source: SEC EDGAR

accession 0001628280-23-028730

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.